Clinical Trials
2 trialsNCT02801578 2020-02-27
A Study of Different Doses of Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)
M.D. Anderson Cancer Center
Phase 2/3 Completed
NCT03642236 2018-08-22
Combination of BTK Inhibitor Overcomes Drug-resistance in Refractory/Relapsed FLT3 Mutant AML
Nanfang Hospital, Southern Medical University
Phase 2/3 Unknown